As purification becomes the bottleneck in oligonucleotide manufacturing, how will the industry rethink scalable, cost‑effective production?

Oligonucleotide therapeutics are advancing quickly, but achieving scalable, sustainable and cost‑efficient manufacturing remains a major challenge.

The oligonucleotide industry presents a pharmaceutical breakthrough. At CPI, we're ensuring this technology makes it beyond labs into the market.

Claire answers some of the most frequently asked questions about oligonucleotides, from a basic definition to their potential within the pharma industry.